pyrroles has been researched along with Obesity in 68 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (4.41) | 18.7374 |
| 1990's | 1 (1.47) | 18.2507 |
| 2000's | 26 (38.24) | 29.6817 |
| 2010's | 33 (48.53) | 24.3611 |
| 2020's | 5 (7.35) | 2.80 |
| Authors | Studies |
|---|---|
| Dikshit, M; Gupta, SK; Jatavallabhula, SL; Kamboj, P; Kumar, A; Kumar, Y; Kumari, D; Mahajan, D; Mukhi, S; Rai, RK; Sarkar, S; Sasibhushan, V; Sharma, V | 1 |
| Kumar, N; Mishra, J; Simonsen, R | 1 |
| Bousquet, P; Fellmann, L; Monassier, L; Niederhoffer, N; Regnard, P; Weiss, M | 1 |
| Shen, Q; Zhang, G | 1 |
| Gaikwad, AN; Goand, UK; Gupta, A; Gupta, S; Kumar, D; Rajan, S; Shankar, K; Srivastava, A; Srivastava, AK; Varshney, S; Vishwakarma, AL | 1 |
| Adams, SE; Brooks, AES; Jaiswal, JK; Jamieson, SMF; Masson, SW; Merry, TL; Shepherd, PR | 1 |
| Aubertin, G; Benameur, D; Bousquet, P; Choquet, P; Dali-Youcef, N; Greney, H; Monassier, L; Niederhoffer, N; Pons, F; Sigrist, S; Traversi, F; Weiss, M | 1 |
| Abraham, NG; Boumaza, I; Faroqui, M; Peterson, SJ; Raza, A; Rubinstein, R; Stec, D; Zhang, Y | 1 |
| Blackhurst, D; Imperial, E; Kamau, F; Mwangi, P; Salie, R; Strijdom, H | 1 |
| Kim, JY; Lee, BH; Lim, CJ; Oh, KS; Yi, KY | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J; Vides, H | 1 |
| Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP | 1 |
| Eleftheriadou, I; Grigoropoulou, P; Katsilambros, N; Makrilakis, K; Margeli, A; Papassotiriou, I; Perrea, D; Tentolouris, N; Zoupas, C | 1 |
| Barrett, PH; Chan, DC; Ng, TW; Ooi, EM; Watts, GF | 1 |
| Droog, S; Havekes, LM; Maas, AC; Offerman, EH; Pieterman, EJ; Princen, HM; van den Hoek, AM; van den Hoogen, RM; van der Hoorn, JW; van Nieuwkoop, A | 1 |
| Chen, ZY; Gao, LH; Lei, L; Li, CN; Liu, Q; Liu, SN; Shen, ZF; Sun, SJ | 1 |
| López-Zapata, DF; Sánchez, JC; Wilkins, RJ | 1 |
| Amrein, KE; Cowan, CA; Ebeling, M; Gérard, R; Hudak, CS; Kiialainen, A; Lee, YK; Meyer, CA; Moisan, A; Prummer, M; Schinzel, RT; Truong, HH; Xia, F; Zhang, JD; Zoffmann, S | 1 |
| Bochar, OM | 1 |
| Bertram, JF; Caruana, G; Dai, L; Fu, P; Howard, V; Jiang, X; Li, J; Nikolic-Paterson, DJ; Puelles, VG; Qu, X; Ren, Y; Sleeman, MW; Sun, YB | 1 |
| Dezentjé, VO; Feberwee, T; van Erp, NP; van Kinschot, CM | 1 |
| Alpini, G; Kumar, N; Meng, F; Mishra, J; Verma, RK | 1 |
| Beijnen, JH; Burger, DM; Desar, IM; Van der Graaf, WT; Van Herpen, CM; Van Hoesel, QG | 1 |
| Byrne, CD; Chipperfield, AJ; Clough, GF; Gamble, J; Krentz, AJ; Turzyniecka, M; Walter, L; Wild, SH | 1 |
| Davy, KP; Dengo, AL; Orr, JS; Rivero, JM | 1 |
| Favaro, RR; Furuya, DT; Machado, UF; Martins, JO; Poletto, AC; Zorn, TM | 1 |
| Huan, Y; Huang, H; Shen, ZF; Song, GM; Sun, SJ; Zhang, N | 1 |
| Acharjee, S; Cannon, CP | 1 |
| Iwai, K; Kitoh, M; Maruta, K; Nagamine, J; Nagata, R; Taiji, M; Tsuchida, A; Ushiroda, K | 1 |
| Caballero, F; Elena, M; Fernández, A; Fernández-Checa, JC; García-Ruiz, C; Llacuna, L; Martínez, L; Matías, N; Montfort, CV; Morales, A; Rimola, A | 1 |
| Wilke, RA | 1 |
| An, LM; Chang, WT; Chen, IJ; Lin, HL; Shen, KP; Wu, BN | 1 |
| Hassanian, MA; Samy, W | 1 |
| Choi, YJ; Geaney, JC; Karpf, DB; Krauss, RM; Naim, S; Roberts, BK; Wang, X; Wojnoonski, K | 1 |
| Ajamieh, H; Chen, J; Chu, E; Farrell, G; Teoh, N; Wong, HJ; Yu, J | 1 |
| El-Moselhy, MA; Heeba, GH; Mourad, AA; Taye, A | 1 |
| Gracia-Sancho, J | 1 |
| Gerasimidis, T; Kadoglou, NP; Kapelouzou, A; Kostakis, A; Liapis, CD; Moumtzouoglou, A; Sailer, N | 1 |
| Artamoshina, NE; Belaya, OL; Bondar, KY; Kuropteva, ZV; Lazutina, OM; Raider, LM; Yakovleva, TV | 1 |
| Andersson, TB; Asberg, A; Bremer, S; Christensen, H; Hjelmesæth, J; Jakobsen, GS; Molden, E; Sandbu, R; Skottheim, IB; Ulvestad, M | 1 |
| Barrett, PH; Beilin, LJ; Chan, DC; Mori, TA; Redgrave, TG; Watts, GF | 3 |
| Barrett, PH; Chan, DC; Croft, KD; Ji, J; Johnson, AG; Loehrer, F; Serone, AP; Watts, GF | 1 |
| Lawrence, JM; Reckless, JP; Reid, J; Stirling, C; Taylor, GJ | 1 |
| Baykan, M; Eminagaoglu, S; Gökçe, M; Orem, A; Orem, C; Uydu, HA; Yilmaz, R | 1 |
| Blanco, S; Egido, J; Gómez-Guerrero, C; López, D; Romero, R; Vaquero, M | 1 |
| Moreno Sánchez, D | 1 |
| Athyros, VG; Didangelos, TP; Elisaf, M; Kakafika, AI; Karagiannis, A; Kleta, D; Mikhailidis, DP; Papageorgiou, AA; Peletidou, A; Tziomalos, K | 1 |
| Ishibashi, S; Kusaka, I; Matsuoka, H; Nagasaka, S; Nakata, M; Yada, T | 1 |
| Hazen, SL; Nicholls, SJ; Nissen, SE; Ntanios, F; Schoenhagen, P; Sipahi, I; Tuzcu, EM; Wun, CC | 1 |
| Barrett, PH; Chan, DC; Nguyen, MN; Watts, GF | 1 |
| Ciccarelli, L; Corradi, L; Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Preti, P; Zoppi, A | 1 |
| Brown, SE; Choi, S; Fan, J; Fathi, Z; Jenkins, S; Kluender, HC; Konkar, A; Lavoie, R; Mays, R; Natoli, J; O'Connor, SJ; Ortiz, AA; Podlogar, B; Smith, RA; Taing, C; Tomlinson, S; Tritto, T; Zhang, Z | 1 |
| Nesto, RW; Singh, PP | 1 |
| Kulbertus, H | 1 |
| Das, S; Gidding, SS; Mitchell, D; Zhang, S | 1 |
| Barrett, PH; Chan, DC; Hegele, RA; van Bockxmeer, FM; Wang, J; Watts, GF | 1 |
| De Angelis, S; De Lorenzo, A; Di Daniele, N; Di Renzo, L; Miani, N; Noce, A; Tozzo, C | 1 |
| Goldstein, MR; Mascitelli, L; Pezzetta, F | 1 |
| Kam, KL; Pfaffendorf, M; van Zwieten, PA | 1 |
| Mertens, A; Muls, E; Vansant, G | 1 |
| Barrett, PH; Chan, DC; James, AP; Mamo, JC; Martins, IJ; Mori, TA; Redgrave, TG; Watts, GF | 1 |
| Barrett, PH; Beilin, LJ; Chan, DC; Mori, TA; Watts, GF | 1 |
| Hill, RG; Hughes, J; Leighton, GE | 1 |
| Bour, H; Denard, Y; Plauchu, M; Rathery, M; Simonin, R; Thervet, F; Warembourg, H | 1 |
| Brown, H; Deleña, S | 1 |
4 review(s) available for pyrroles and Obesity
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Office-based global cardiometabolic risk assessment: a simple tool incorporating nontraditional markers.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Obesity; Office Visits; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Risk Assessment; Smoking; United States | 2010 |
High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Databases, Nucleic Acid; Dose-Response Relationship, Drug; Dyslipidemias; Electronic Health Records; Genetic Association Studies; Genetic Markers; Heptanoic Acids; Humans; Obesity; Pravastatin; Pyrroles; Risk Assessment; Simvastatin; Treatment Outcome | 2011 |
[Medical management of primary nonalcoholic fatty liver disease].
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fatty Liver; Heptanoic Acids; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metabolic Syndrome; Metformin; Obesity; Orlistat; Prevalence; Pyrroles; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
22 trial(s) available for pyrroles and Obesity
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Obesity; Peptide Fragments; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Effect of atorvastatin on baroreflex sensitivity in subjects with type 2 diabetes and dyslipidaemia.
Topics: Aged; Atorvastatin; Baroreflex; Body Mass Index; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Diet, Fat-Restricted; Dyslipidemias; Female; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myalgia; Obesity; Patient Dropouts; Prospective Studies; Pyrroles; Risk Factors | 2014 |
Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men.
Topics: Anticholesteremic Agents; Apolipoprotein B-100; Atorvastatin; Docosahexaenoic Acids; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Eicosapentaenoic Acid; Heptanoic Acids; Humans; Insulin Resistance; Lipoproteins, VLDL; Male; Middle Aged; Obesity; Pyrroles; Treatment Outcome; Triglycerides | 2014 |
Combined effect of appointment telmisartan and atorvastatin on hemodynamic indicators and the indicators of lipid profile in patients with arterial hypertension combined with obesity and steatohepatitis.
Topics: Acetamides; Adipokines; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Benzoates; Breath Tests; Cholesterol, LDL; Drug Therapy, Combination; Fatty Liver; Female; Hemodynamics; Heptanoic Acids; Humans; Hypertension; Lipids; Male; Middle Aged; Obesity; Pyrroles; Telmisartan; Triglycerides | 2014 |
Muscle microvascular dysfunction in central obesity is related to muscle insulin insensitivity but is not reversed by high-dose statin treatment.
Topics: Adolescent; Adult; Aged; Atorvastatin; Biological Transport; Blood Pressure; Double-Blind Method; Energy Metabolism; Exercise Test; Female; Glucose; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Lipids; Male; Microcirculation; Middle Aged; Muscle, Skeletal; Obesity; Pyrroles | 2009 |
Arterial destiffening with atorvastatin in overweight and obese middle-aged and older adults.
Topics: Adult; Aged; Aging; Atorvastatin; Blood Flow Velocity; C-Reactive Protein; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Double-Blind Method; Elasticity; Female; Femoral Artery; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Obesity; Overweight; Pyrroles; Regional Blood Flow; Risk Factors | 2009 |
Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.
Topics: Adult; Alanine Transaminase; Anticholesteremic Agents; Aryldialkylphosphatase; Aspartate Aminotransferases; Atorvastatin; Cholesterol; Cross-Sectional Studies; Disease Progression; Fatty Liver; Female; Glutathione Peroxidase; Hepatitis; Heptanoic Acids; Humans; Lipid Peroxidation; Lipoproteins, HDL; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Pyrroles; Risk Factors; Triglycerides | 2011 |
Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia.
Topics: Acetates; Analysis of Variance; Atherosclerosis; Atorvastatin; Biomarkers; Chi-Square Distribution; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Obesity; Overweight; Particle Size; PPAR gamma; Pyrroles; Time Factors; Treatment Outcome; Triazoles | 2012 |
Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.
Topics: Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Fasting; Fatty Acids, Nonesterified; Fish Oils; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insulin; Insulin Resistance; Kinetics; Male; Middle Aged; Obesity; Placebos; Pyrroles | 2002 |
Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
Topics: Adult; Apolipoprotein A-I; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diet; Double-Blind Method; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Insulin; Kinetics; Lipoproteins; Lipoproteins, HDL; Lipoproteins, IDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Metabolic Syndrome; Middle Aged; Obesity; Placebos; Pyrroles; Triglycerides | 2003 |
The effect of high dose atorvastatin therapy on lipids and lipoprotein subfractions in overweight patients with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Apolipoproteins B; Atorvastatin; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Lipid Metabolism; Lipoproteins; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Obesity; Pyrroles; Reference Values; Treatment Outcome | 2004 |
Targeting vascular risk in patients with metabolic syndrome but without diabetes.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Diabetes Mellitus; Drug Therapy, Combination; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Metabolic Syndrome; Middle Aged; Obesity; Prevalence; Prospective Studies; Pyrroles; Risk Factors; Risk Reduction Behavior | 2005 |
Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Body Mass Index; C-Reactive Protein; Coronary Disease; Coronary Vessels; Disease Progression; Endosonography; Female; Heptanoic Acids; Humans; Inflammation; Lipids; Male; Middle Aged; Obesity; Pravastatin; Pyrroles; Risk Factors | 2006 |
Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity.
Topics: Abdominal Fat; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein A-II; Atorvastatin; Dietary Supplements; Double-Blind Method; Drug Therapy, Combination; Fatty Acids, Omega-3; Fish Oils; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hyperlipidemias; Insulin Resistance; Kinetics; Lipoproteins, HDL; Male; Middle Aged; Obesity; Placebos; Pyrroles; Treatment Outcome | 2006 |
Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients.
Topics: Adult; Aged; Amlodipine; Atorvastatin; Biomarkers; Blood Glucose; Body Mass Index; Calcium Channel Blockers; Cholesterol; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Inflammation; Insulin Resistance; Interleukin-6; Male; Middle Aged; Obesity; Pyrroles; Tablets; Tumor Necrosis Factor-alpha | 2006 |
Variation in Niemann-Pick C1-like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men.
Topics: Adult; Anti-Obesity Agents; Apolipoprotein B-100; Atorvastatin; Cholesterol, VLDL; Drug Resistance; Genetic Variation; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Male; Membrane Proteins; Membrane Transport Proteins; Middle Aged; Obesity; Pyrroles; Treatment Outcome | 2008 |
The effect of atorvastatin on postprandial lipaemia in overweight or obese women homozygous for apo E3.
Topics: Adult; Apolipoprotein E3; Apolipoproteins E; Atorvastatin; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL; Double-Blind Method; Energy Intake; Female; Heptanoic Acids; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Obesity; Polymerase Chain Reaction; Postprandial Period; Pyrroles; Triglycerides | 2001 |
Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test.
Topics: Anticholesteremic Agents; Atorvastatin; Body Mass Index; Breath Tests; Carbon Dioxide; Carbon Isotopes; Cholesterol; Chylomicron Remnants; Chylomicrons; Double-Blind Method; Heptanoic Acids; Humans; Hyperlipidemias; Lipoproteins; Obesity; Placebos; Pyrroles; Time Factors; Triglycerides; Viscera | 2002 |
Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
Topics: Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lipoproteins; Lipoproteins, IDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Obesity; Pyrroles; Viscera | 2002 |
Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Colorimetry; Cross-Sectional Studies; Enzyme Inhibitors; Fish Oils; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Immunoassay; Interleukin-6; Male; Middle Aged; Obesity; Pyrroles; Tumor Necrosis Factor-alpha | 2002 |
Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity.
Topics: Atorvastatin; Diet; Double-Blind Method; Drug Synergism; Exercise; Fish Oils; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lipoproteins; Male; Middle Aged; Obesity; Placebos; Pyrroles; Risk Factors | 2002 |
43 other study(ies) available for pyrroles and Obesity
| Article | Year |
|---|---|
Saroglitazar and Hepano treatment offers protection against high fat high fructose diet induced obesity, insulin resistance and steatosis by modulating various class of hepatic and circulating lipids.
Topics: Animals; Cell Line; Diet; Diet, High-Fat; Fatty Liver; Fructose; Humans; Hypolipidemic Agents; Insulin Resistance; Lipid Metabolism; Lipidomics; Lipids; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; Phenylpropionates; Pyrroles | 2021 |
Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; beta Catenin; Biological Transport; Colon; Epithelial Cells; HT29 Cells; Humans; Insulin; Intestinal Mucosa; Janus Kinase 3; Mice; Mice, Knockout; Neoplasm Proteins; Obesity; Phosphorylation; Piperidines; Pyrimidines; Pyrroles; Tissue Inhibitor of Metalloproteinase-1 | 2019 |
Protective effects of the imidazoline-like drug lnp599 in a marmoset model of obesity-induced metabolic disorders.
Topics: Aniline Compounds; Animals; Body Weight; Callithrix; Disease Models, Animal; Imidazolines; Male; Metabolic Diseases; Obesity; Protective Agents; Pyrroles | 2021 |
Depletion of microglia mitigates cerebrovascular dysfunction in diet-induced obesity mice.
Topics: Aminopyridines; Animals; Basilar Artery; Cerebrovascular Disorders; Encephalitis; Male; Mice, Inbred C57BL; Microglia; Obesity; Pyrroles | 2021 |
Saroglitazar reduces obesity and associated inflammatory consequences in murine adipose tissue.
Topics: Adipose Tissue; Animals; Energy Metabolism; Glucose; Homeostasis; Hypertrophy; Inflammation; Male; Mice; Mice, Inbred C57BL; Obesity; Organ Specificity; Phenylpropionates; Pyrroles | 2018 |
The CSF1 receptor inhibitor pexidartinib (PLX3397) reduces tissue macrophage levels without affecting glucose homeostasis in mice.
Topics: Adipose Tissue; Aminopyridines; Animals; Diet, High-Fat; Glucose; Homeostasis; Insulin Resistance; Macrophages; Mice; Obesity; Pyrroles; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 2020 |
Effects of imidazoline-like drugs on liver and adipose tissues, and their role in preventing obesity and associated cardio-metabolic disorders.
Topics: Adipose Tissue; Aniline Compounds; Animals; Body Weight; Eating; Hep G2 Cells; Humans; Imidazolines; Liver; Male; Metabolic Diseases; Obesity; Pyrroles; Rats; Rats, Zucker | 2019 |
Positive Effects of Heme Oxygenase Upregulation on Adiposity and Vascular Dysfunction: Gene Targeting vs. Pharmacologic Therapy.
Topics: Adiposity; Animals; Cell Line; Endothelial Cells; Enzyme Activators; Gene Targeting; Genetic Therapy; Heme Oxygenase-1; Male; Mice, Inbred C57BL; Obesity; Pyrazines; Pyrroles; Up-Regulation; Vasodilation | 2019 |
Antiretroviral drug-induced endothelial dysfunction is improved by dual PPARα/γ stimulation in obesity.
Topics: Animals; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Aorta, Thoracic; Disease Models, Animal; Endothelium, Vascular; Male; NADPH Oxidases; Nitric Oxide Synthase Type III; Obesity; Phenylpropionates; PPAR alpha; PPAR gamma; Proto-Oncogene Proteins c-akt; Pyrroles; Rats, Wistar; Signal Transduction; Vasodilation | 2019 |
Synthesis and SAR study of pyrrolo[3,4-b]pyridin-7(6H)-one derivatives as melanin concentrating hormone receptor 1 (MCH-R1) antagonists.
Topics: Animals; Anti-Obesity Agents; Half-Life; Humans; Obesity; Protein Binding; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Rats; Receptors, Pituitary Hormone; Structure-Activity Relationship | 2013 |
Are statins 'IDEAL' for non-alcoholic fatty liver disease?
Topics: Atorvastatin; Carcinoma, Hepatocellular; Cardiovascular Diseases; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Liver; Liver Neoplasms; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Triglycerides | 2014 |
APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Apolipoprotein E3; Atorvastatin; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Fenofibrate; Glucagon-Like Peptide 1; Heptanoic Acids; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Liraglutide; Male; Metabolic Syndrome; Mice, Transgenic; Niacin; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Rosiglitazone; Thiazolidinediones | 2014 |
Atorvastatin helps preserve pancreatic β cell function in obese C57BL/6 J mice and the effect is related to increased pancreas proliferation and amelioration of endoplasmic-reticulum stress.
Topics: Animals; Apoptosis; Atorvastatin; Blotting, Western; Cell Survival; Endoplasmic Reticulum Stress; Fluorescent Antibody Technique; Heptanoic Acids; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Obesity; Pancreas; Pyrroles; Real-Time Polymerase Chain Reaction | 2014 |
TRPV4 channels activity in bovine articular chondrocytes: regulation by obesity-associated mediators.
Topics: Animals; Calcium; Cartilage, Articular; Cattle; Cells, Cultured; Chondrocytes; Gadolinium; Insulin; Interleukin-1beta; Leptin; Morpholines; Obesity; Osmotic Pressure; Patch-Clamp Techniques; Pyrroles; Resistin; Ruthenium Red; TRPV Cation Channels; Tumor Necrosis Factor-alpha | 2014 |
White-to-brown metabolic conversion of human adipocytes by JAK inhibition.
Topics: Adipocytes, Brown; Adipocytes, White; Animals; Bone Morphogenetic Protein 7; Cell Differentiation; Cells, Cultured; Gene Expression Profiling; Hedgehog Proteins; Humans; Interferon-gamma; Ion Channels; Janus Kinase 1; Janus Kinase 3; Male; Mice; Mice, Inbred C57BL; Mitochondria; Mitochondrial Proteins; Obesity; Oxazines; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; STAT1 Transcription Factor; STAT3 Transcription Factor; Tumor Necrosis Factor-alpha; Uncoupling Protein 1; Veratrum Alkaloids | 2015 |
Smad3 deficiency protects mice from obesity-induced podocyte injury that precedes insulin resistance.
Topics: Animals; Cells, Cultured; Dietary Fats; Enzyme Inhibitors; Fibrosis; Flavonoids; Gene Knockdown Techniques; Insulin; Insulin Resistance; Isoquinolines; Male; Mice; Mice, Inbred C57BL; Microfilament Proteins; Mitochondria; Obesity; Palmitic Acid; Phosphorylation; Piperidines; Podocytes; Protective Factors; Protein Kinase Inhibitors; Pyridines; Pyrroles; Signal Transduction; Smad3 Protein | 2015 |
Sunitinib treatment in a patient with metastatic renal cell carcinoma and bariatric surgery.
Topics: Bariatric Surgery; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Indoles; Kidney Neoplasms; Male; Obesity; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2015 |
Role of Janus Kinase 3 in Predisposition to Obesity-associated Metabolic Syndrome.
Topics: Animals; Body Weight; Caco-2 Cells; Cytokines; Diet, High-Fat; Disease Models, Animal; Genetic Predisposition to Disease; Glucose Tolerance Test; Humans; Immunity, Innate; Inflammation; Insulin; Janus Kinase 3; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Knockout; Microscopy, Fluorescence; Obesity; Organ Size; Piperidines; Pyrimidines; Pyrroles; Risk Factors; Signal Transduction; Toll-Like Receptors | 2015 |
Pharmacokinetics of sunitinib in an obese patient with a GIST.
Topics: Adult; Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Obesity; Pyrroles; Sunitinib | 2009 |
Anti-inflammatory effect of atorvastatin ameliorates insulin resistance in monosodium glutamate-treated obese mice.
Topics: Adipose Tissue, White; Animals; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Blood Glucose; Cytokines; Enzyme-Linked Immunosorbent Assay; Glucose Transporter Type 4; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; I-kappa B Kinase; Immunohistochemistry; Insulin Resistance; Lipids; Male; Mice; Obesity; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA; Sodium Glutamate | 2010 |
Atorvastatin improves insulin sensitivity in mice with obesity induced by monosodium glutamate.
Topics: Adipose Tissue; Administration, Oral; Animals; Atorvastatin; Blood Glucose; Blotting, Western; Disease Models, Animal; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Lipid Metabolism; Mice; Mice, Inbred ICR; Obesity; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sodium Glutamate | 2010 |
Development of a new class of benzoylpyrrole-based PPARα/γ activators.
Topics: Acetates; Animals; Carboxylic Acids; Hyperglycemia; Hypoglycemic Agents; Male; Mice; Mice, Obese; Obesity; PPAR alpha; PPAR gamma; Pyrroles; Rats; Structure-Activity Relationship | 2011 |
Targeting cholesterol at different levels in the mevalonate pathway protects fatty liver against ischemia-reperfusion injury.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol, Dietary; Choline; Choline Deficiency; Disease Models, Animal; Disease Susceptibility; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Fatty Liver; Glutathione; Heptanoic Acids; Lipotropic Agents; Liver; Male; Mevalonic Acid; Mice; Mice, Inbred C57BL; Mitochondria; Obesity; Pyrroles; Quinuclidines; Reperfusion Injury | 2011 |
Suppression of inflammatory response and endothelial nitric oxide synthase downregulation in hyperlipidaemic C57BL/6J mice by eugenosedin-A.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Atorvastatin; Dietary Fats; Down-Regulation; Endothelium, Vascular; Female; Heptanoic Acids; Hyperlipidemias; Inflammation; Interferon-gamma; Liver; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Nitric Oxide; Nitric Oxide Synthase Type III; Obesity; Piperazines; Pyrroles; Random Allocation; RNA, Messenger; Tumor Necrosis Factor-alpha | 2011 |
Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation.
Topics: Administration, Oral; Animals; Atorvastatin; Cell Adhesion Molecules; Cytokines; Cytoprotection; Disease Models, Animal; Down-Regulation; Drug Administration Schedule; Enzyme Activation; Fatty Liver; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intravenous; Liver; Male; Mice; Mice, Obese; NF-kappa B; Nitric Oxide Synthase Type III; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Reperfusion Injury; RNA, Messenger; Thromboxane B2; Time Factors; Toll-Like Receptor 4 | 2012 |
Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Therapy, Combination; Heptanoic Acids; Hypercholesterolemia; Hyperglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Losartan; Male; Obesity; Pioglitazone; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2013 |
Enhancing organ pool by statins: is this the future?
Topics: Animals; Atorvastatin; Fatty Liver; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Nitric Oxide Synthase Type III; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Reperfusion Injury; Toll-Like Receptor 4 | 2012 |
Adipokines: a novel link between adiposity and carotid plaque vulnerability.
Topics: Adiposity; Aged; Anticholesteremic Agents; Apelin; Atorvastatin; Body Mass Index; Cholesterol, LDL; Cytokines; Female; Heptanoic Acids; Humans; Image Interpretation, Computer-Assisted; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Obesity; Plaque, Atherosclerotic; Predictive Value of Tests; Prospective Studies; Pyrroles; Risk Factors; Ultrasonography, Doppler, Color | 2012 |
[Atorvastatin and oxidative stress in coronary heart disease with obesity].
Topics: Adult; Aged; Antioxidants; Atorvastatin; Case-Control Studies; Coronary Disease; Dyslipidemias; Electrocardiography, Ambulatory; Electron Spin Resonance Spectroscopy; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Lipids; Middle Aged; Obesity; Oxidative Stress; Pyrroles | 2012 |
Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects.
Topics: Adult; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Body Mass Index; Cytochrome P-450 CYP3A; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Mucosa; Liver; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Obesity; Organic Anion Transporters; Pyrroles | 2013 |
The effects of atorvastatin treatment on the fibrinolytic system in dyslipidemic patients.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Diet, Fat-Restricted; Drug Administration Schedule; Female; Fibrinolysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Obesity; Plasminogen Activator Inhibitor 1; Pyrroles; Risk Factors; Smoking; Tissue Plasminogen Activator; Triglycerides | 2004 |
Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glomerulosclerosis, Focal Segmental; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunoenzyme Techniques; Kidney; Kidney Glomerulus; Linear Models; Microscopy, Electron; Obesity; Pyrroles; Quinapril; Rats; Rats, Zucker; Staining and Labeling; Tetrahydroisoquinolines | 2005 |
Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control.
Topics: 3T3 Cells; Adipocytes; Animals; Atorvastatin; Biological Transport; Blood Glucose; Cell Differentiation; Cellular Senescence; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Glucose Transporter Type 4; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Middle Aged; Obesity; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Constrained analogs of CB-1 antagonists: 1,5,6,7-Tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivatives.
Topics: Animals; Anti-Obesity Agents; Body Weight; Crystallography, X-Ray; Drug Design; Eating; Humans; Magnetic Resonance Spectroscopy; Male; Models, Molecular; Obesity; Piperidines; Pyrazoles; Pyridones; Pyrroles; Rats; Rats, Wistar; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant; Structure-Activity Relationship; Weight Gain | 2007 |
Diabetes and residual risk of coronary heart disease.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Heptanoic Acids; Humans; Insulin Resistance; Obesity; Pyrroles; Risk Factors; Simvastatin | 2007 |
[The 2006 American Heart Association selection of the "top ten advances in heart disease and stroke research"].
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; American Heart Association; Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Brain Ischemia; Child; Coronary Disease; Heart Diseases; Heart Valve Prosthesis; Heart-Assist Devices; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Obesity; Peptidyl-Dipeptidase A; Process Assessment, Health Care; Pyrroles; Stroke; Tissue Engineering; United States | 2007 |
Metabolic syndrome with early aortic atherosclerosis in a child.
Topics: Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Atorvastatin; Child; Cholesterol; Cholesterol, HDL; Fish Oils; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Magnetic Resonance Imaging; Male; Metabolic Syndrome; Obesity; Pyrroles; Treatment Outcome; Triglycerides | 2006 |
Anti-inflammatory effects of combined treatment with acetyl salicylic acid and atorvastatin in haemodialysis patients affected by Normal Weight Obese syndrome.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Atorvastatin; Body Fat Distribution; Body Mass Index; Body Weight; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Inflammation; Kidney Failure, Chronic; Lipid Metabolism; Male; Middle Aged; Nutrition Assessment; Obesity; Prealbumin; Pyrroles; Renal Dialysis; Serum Albumin; Syndrome | 2008 |
Statins, leptin and regulatory T cells.
Topics: Animals; Atorvastatin; Heptanoic Acids; Humans; Leptin; Lymphocyte Activation; Neoplasms; Obesity; Pyrroles; Risk Factors; T-Lymphocytes, Regulatory; Thinness | 2008 |
Pharmacodynamic behaviour of isolated resistance vessels obtained from hypertensive-diabetic rats.
Topics: Animals; Benzopyrans; Blood Glucose; Calcium Channels; Calcium Chloride; Cromakalim; Glyburide; Hypertension; In Vitro Techniques; Male; Mesenteric Arteries; Methacholine Chloride; Methoxamine; Muscle Contraction; Muscle, Smooth; Nifedipine; Nitroprusside; Norepinephrine; Obesity; Potassium Channels; Potassium Chloride; Pyrroles; Rats; Rats, Zucker; Serotonin; Tunica Media; Vascular Resistance; Vasoconstrictor Agents; Vasodilator Agents | 1996 |
The effects of the kappa agonist PD-117302 on feeding behaviour in obese and lean Zucker rats.
Topics: Animals; Eating; Feeding Behavior; Hyperphagia; Male; Obesity; Pyrroles; Rats; Rats, Zucker; Receptors, Opioid; Receptors, Opioid, kappa; Thiophenes | 1988 |
[A new antidiabetic agent: glyclazide. A study of glycemic regulation].
Topics: Adult; Aged; Blood Glucose; Cyclopentanes; Diabetes Mellitus; Female; Gluconeogenesis; Glycolysis; Glycosuria; Humans; Hypoglycemic Agents; Male; Middle Aged; Obesity; Pyrroles; Statistics as Topic; Sulfonylurea Compounds; Time Factors | 1974 |
Effect of glycine loading on Delta-Aminolevulinic acid (ALA) and porphobilinogen (PBG) excretion during starvation.
Topics: Adolescent; Adult; Amino Acids; Body Weight; Female; Glycine; Humans; Hydro-Lyases; Levulinic Acids; Male; Middle Aged; Obesity; Porphyrias; Porphyrins; Propionates; Pyrroles; Starvation | 1969 |